Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||triple-receptor negative breast cancer||not applicable||Sacituzumab govitecan-hziy||FDA approved||Actionable||In a Phase I/II trial (IMMU-132-01) that supported FDA approval, Trodelvy (sacituzumab govitecan-hziy) treatment resulted in an objective response rate of 33.3% (36/108, 3 complete response, 33 partial response) and a clinical benefit rate of 45.4% in patients with metastatic triple-negative breast cancer who received two or more prior therapies, with a median duration of response, progression-free survival, and overall survival of 7.7, 5.5, and 13.0 months respectively (PMID: 30786188; NCT01631552).||30786188 detail...|
|Unknown unknown||triple-receptor negative breast cancer||not applicable||Sacituzumab govitecan-hziy||Case Reports/Case Series||Actionable||In a Phase I/II trial (IMMU-132-01), Trodelvy (sacituzumab govitecan-hziy) treatment resulted in a partial response in a patient with triple-negative breast cancer (PMID: 25944802; NCT01631552).||25944802|
|PubMed Id||Reference Title||Details|
|(25944802)||First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors.||Full reference...|
|Trodelvy (sacituzumab govitecan-hziy) FDA Drug Label||Full reference...|
|(30786188)||Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.||Full reference...|